Marksans Pharma Ltd Quarterly Results
Q4 FY25-26 Results Summary
Revenue
The revenue stands at ₹856.11 crore, reflecting a quarter-on-quarter *(QoQ) increase of 13.48 per cent from ₹754.43 crore. This corresponds to a year-on-year *(YoY) growth of 20.84 per cent.
Operating Profit
Operating Profit stands at ₹195.42 crore, reflecting a quarter-on-quarter *(QoQ) increase of 21.58 per cent from ₹160.74 crore. This corresponds to a year-on-year *(YoY) growth of 53.95 per cent.
PBDT
PBDT stands at ₹224.29 crore, reflecting a quarter-on-quarter *(QoQ) increase of 28.20 per cent from ₹174.96 crore. This corresponds to a year-on-year *(YoY) growth of 61.55 per cent.
Profit Before Tax
Profit Before Tax stands at ₹200.00 crore, reflecting a quarter-on-quarter *(QoQ) increase of 32.78 per cent from ₹150.63 crore. This corresponds to a year-on-year *(YoY) growth of 72.27 per cent.
Net Profit
Net Profit stands at ₹149.03 crore, reflecting a quarter-on-quarter *(QoQ) increase of 31.08 per cent from ₹113.69 crore. This represents a 64.26 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Marksans Pharma Ltd Earnings
- YOY
- QOQ
Marksans Pharma Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Marksans Pharma Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Marksans Pharma Ltd Financial Reports
Marksans Pharma Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Marksans Pharma | 2.28% | 3.16% | 19.32% | 59.37% | 44.36% | 8.26% |
| Jubilant Pharmo | 0.16% | -3.32% | -4.73% | 11.69% | -10.10% | -14.35% |
| Concord Biotech | -1.42% | -1.76% | 16.20% | 26.91% | -2.24% | -26.04% |
| Alivus Life | 3.06% | 6.63% | 6.80% | 15.51% | 23.62% | 12.56% |
| Viyash Scientific | 0.35% | 11.42% | 4.45% | 44.05% | 27.43% | 48.61% |
| Corona Remedies | 3.56% | 6.77% | 12.62% | 21.68% | 42.05% | 33.16% |
| Shilpa Medicare | 6.94% | 1.92% | 14.06% | 72.33% | 82.17% | 34.81% |
Company Info
Company Information
Chairman & Managing Director : Mark Saldanha
Company Sec. & Compli. Officer : Harshavardhan Panigrahi
Whole-time Director : Sandra Saldanha
Independent Director : Digant Mahesh Parikh
Whole-time Director : Varddhman Vikramaditya Jain
Independent Director : Abhinna Sundar Mohanty
Non Executive Director : Sunny Sharma
Independent Director : Shailaja Vardhan
Independent Director : Srinivas Mishra